|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 4 (August 15), 1999:
pp. 1465-1470
Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Blood
Stem Cell Transplantation
Donna Przepiorka,
Terry L. Smith,
Jody Folloder,
Issa Khouri,
Naoto T. Ueno,
Rakesh Mehra,
Martin Körbling,
Yang O. Huh,
Sergio Giralt,
James Gajewski,
Michele Donato,
Karen Cleary,
David Claxton,
Ira Braunschweig,
Koen van Besien,
Borje S. Andersson,
Paolo Anderlini, and
Richard Champlin
From the Departments of Blood and Marrow Transplantation,
Biomathematics, Laboratory Medicine and Pathology, University of Texas
M.D. Anderson Cancer Center, Houston, TX
We evaluated demographic characteristics and graft composition as
risk factors for acute graft-versus-host disease (GVHD) in 160 adult
recipients of HLA-identical allogeneic blood stem cell transplants. The
patients received a median nucleated cell dose of 7.9 × 108/kg and median C34+ cell dose of 5.6 × 106/kg. GVHD prophylaxis consisted of cyclosporine (CSA)
and steroids, tacrolimus (FK506) and steroids, or FK506 and
methotrexate. Grades 2 to 4 GVHD occurred in 31% (95% CI, 23% to
39%), and grades 3 to 4 GVHD in 14% (95% CI, 8% to 20%). In
univariate analyses, GVHD prophylaxis with CSA and high
CD34+ cell doses were significant risk factors for grades
2 to 4 GVHD, but diagnosis, age, use of total body irradiation, donor
sex, female donor for male recipient, donor parity, donor
alloimmunization, viral serology, nucleated cell dose,
CD3+ cell dose, and CD56+ cell dose did not
alter the incidence of GVHD significantly. With a CD34+
cell dose less than 8 × 106 CD34+ cells/kg,
the risk of grades 2 to 4 GVHD was significantly higher for those who
received CSA (39%, 95% CI, 21% to 47%) in comparison with those on
FK506 (18%, 95% CI, 10% to 26%) (P = .03), but GVHD prophylaxis regimen had less impact with a higher CD34+
cell dose (overall grades 2 to 4 GVHD rate 52%, 95% CI, 37% to 67%). GVHD prophylaxis and CD34+ cell dose are
independent risk factors for acute GVHD after allogeneic blood stem
cell transplantation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. W. Chien, M. J. Boeckh, J. A. Hansen, and J. G. Clark
Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation
Blood,
February 15, 2008;
111(4):
2462 - 2469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Jakubowski, T. N. Small, J. W. Young, N. A. Kernan, H. Castro-Malaspina, K. C. Hsu, M.-A. Perales, N. Collins, C. Cisek, M. Chiu, et al.
T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
Blood,
December 15, 2007;
110(13):
4552 - 4559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Pabst, H. Schirutschke, G. Ehninger, M. Bornhauser, and U. Platzbecker
The Graft Content of Donor T Cells Expressing {gamma}{delta}TCR+ and CD4+foxp3+ Predicts the Risk of Acute Graft versus Host Disease after Transplantation of Allogeneic Peripheral Blood Stem Cells from Unrelated Donors
Clin. Cancer Res.,
May 15, 2007;
13(10):
2916 - 2922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, J. Cortes, H. M. Kantarjian, S. Giralt, D. Jones, R. Jones, F. Giles, B. S. Andersson, R. Champlin, and M. de Lima
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure
Blood,
August 15, 2006;
108(4):
1421 - 1423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rezvani, S. Mielke, M. Ahmadzadeh, Y. Kilical, B. N. Savani, J. Zeilah, K. Keyvanfar, A. Montero, N. Hensel, R. Kurlander, et al.
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT
Blood,
August 15, 2006;
108(4):
1291 - 1297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Abbasian, D. Mahmud, N. Mahmud, S. Chunduri, H. Araki, P. Reddy, R. Hoffman, M. Arpinati, J. L. M. Ferrara, and D. Rondelli
Allogeneic T cells induce rapid CD34+ cell differentiation into CD11c+CD86+ cells with direct and indirect antigen-presenting function
Blood,
July 1, 2006;
108(1):
203 - 208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Chien, L. P. Zhao, J. A. Hansen, W. H. Fan, T. Parimon, and J. G. Clark
Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation
Blood,
March 1, 2006;
107(5):
2200 - 2207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. N. Savani, K. Rezvani, S. Mielke, A. Montero, R. Kurlander, C. S. Carter, S. Leitman, E. J. Read, R. Childs, and A. J. Barrett
Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia
Blood,
February 15, 2006;
107(4):
1688 - 1695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Schmid, M. Schleuning, G. Ledderose, J. Tischer, and H.-J. Kolb
Sequential Regimen of Chemotherapy, Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation, and Prophylactic Donor Lymphocyte Transfusion in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
J. Clin. Oncol.,
August 20, 2005;
23(24):
5675 - 5687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Parimon, D. K. Madtes, D. H. Au, J. G. Clark, and J. W. Chien
Pretransplant Lung Function, Respiratory Failure, and Mortality after Stem Cell Transplantation
Am. J. Respir. Crit. Care Med.,
August 1, 2005;
172(3):
384 - 390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. de Lima, D. Couriel, P. F. Thall, X. Wang, T. Madden, R. Jones, E. J. Shpall, M. Shahjahan, B. Pierre, S. Giralt, et al.
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
Blood,
August 1, 2004;
104(3):
857 - 864.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stanzani, S. L. R. Martins, R. M. Saliba, L. S. St. John, S. Bryan, D. Couriel, J. McMannis, R. E. Champlin, J. J. Molldrem, and K. V. Komanduri
CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans
Blood,
February 1, 2004;
103(3):
1140 - 1146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Perez-Simon, M. Diez-Campelo, R. Martino, A. Sureda, D. Caballero, C. Canizo, S. Brunet, A. Altes, L. Vazquez, J. Sierra, et al.
Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation
Blood,
August 1, 2003;
102(3):
1108 - 1113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Chien, P. J. Martin, T. A. Gooley, M. E. Flowers, S. R. Heckbert, W. G. Nichols, and J. G. Clark
Airflow Obstruction after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Am. J. Respir. Crit. Care Med.,
July 15, 2003;
168(2):
208 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Cottler-Fox, T. Lapidot, I. Petit, O. Kollet, J. F. DiPersio, D. Link, and S. Devine
Stem Cell Mobilization
Hematology,
January 1, 2003;
2003(1):
419 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Couban, D. R. Simpson, M. J. Barnett, C. Bredeson, L. Hubesch, K. Howson-Jan, T. B. Shore, I. R. Walker, P. Browett, H. A. Messner, et al.
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies
Blood,
August 13, 2002;
100(5):
1525 - 1531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Urbano-Ispizua, C. Rozman, P. Pimentel, C. Solano, J. de la Rubia, S. Brunet, J. Perez-Oteyza, C. Ferra, J. Zuazu, D. Caballero, et al.
Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings
Blood,
June 28, 2002;
100(2):
724 - 727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Guardiola, V. Runde, A. Bacigalupo, T. Ruutu, F. Locatelli, M. A. Boogaerts, A. Pagliuca, J. J. Cornelissen, H. C. Schouten, E. Carreras, et al.
Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes
Blood,
May 29, 2002;
99(12):
4370 - 4378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehta, S. Singhal, C. Cutler, and J. H. Antin
Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell Transplantation: A Little Methotrexate Goes a Long Way
J. Clin. Oncol.,
January 15, 2002;
20(2):
603 - 606.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Khouri, R. M. Saliba, S. A. Giralt, M.-S. Lee, G.-J. Okoroji, F. B. Hagemeister, M. Korbling, A. Younes, C. Ippoliti, J. L. Gajewski, et al.
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality
Blood,
December 15, 2001;
98(13):
3595 - 3599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Zaucha, T. Gooley, W. I. Bensinger, S. Heimfeld, T. R. Chauncey, R. Zaucha, P. J. Martin, M. E. D. Flowers, J. Storek, G. Georges, et al.
CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation
Blood,
December 1, 2001;
98(12):
3221 - 3227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Urbano-Ispizua, E. Carreras, P. Marin, M. Rovira, C. Martinez, F. Fernandez-Aviles, B. Xicoy, J.-C. Hernandez-Boluda, and E. Montserrat
Allogeneic transplantation of CD34+ selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34+ cells?
Blood,
October 15, 2001;
98(8):
2352 - 2357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kollman, C. W. S. Howe, C. Anasetti, J. H. Antin, S. M. Davies, A. H. Filipovich, J. Hegland, N. Kamani, N. A. Kernan, R. King, et al.
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age
Blood,
October 1, 2001;
98(7):
2043 - 2051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Przepiorka, P. Anderlini, R. Saliba, K. Cleary, R. Mehra, I. Khouri, Y. O. Huh, S. Giralt, I. Braunschweig, K. van Besien, et al.
Chronic graft-versus-host disease after allogeneic blood stem cell transplantation
Blood,
September 15, 2001;
98(6):
1695 - 1700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. J. van Esser, B. van der Holt, E. Meijer, H. G. M. Niesters, R. Trenschel, S. F. T. Thijsen, A. M. van Loon, F. Frassoni, A. Bacigalupo, U. W. Schaefer, et al.
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT
Blood,
August 15, 2001;
98(4):
972 - 978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. K. Waller, H. Rosenthal, T. W. Jones, J. Peel, S. Lonial, A. Langston, I. Redei, I. Jurickova, and M. W. Boyer
Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation
Blood,
May 15, 2001;
97(10):
2948 - 2956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cutler and J. H. Antin
Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review
Stem Cells,
February 1, 2001;
19(2):
108 - 117.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. E. Champlin, N. Schmitz, M. M. Horowitz, B. Chapuis, R. Chopra, J. J. Cornelissen, R. P. Gale, J. M. Goldman, F. R. Loberiza Jr, B. Hertenstein, et al.
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
Blood,
June 15, 2000;
95(12):
3702 - 3709.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
